Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mitani

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Oncogene|November 11, 1999
Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domainsJ Yan, H Kuroyanagi, T Tomemori, et al.
Archives of Gerontology and Geriatrics|December 20, 2011
Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) studyN Kuriyama, T Mizuno, Y Ohshima, et al.
Neuron|October 18, 2001
C. elegans slit acts in midline, dorsal-ventral, and anterior-posterior guidance via the SAX-3/Robo receptorJ C Hao, T W Yu, K Fujisawa, et al.
Leukemia|January 9, 2015
High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AMLA Jo, S Mitani, N Shiba, et al.
ESMO Open|November 28, 2023
Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational studyY Narita, T Matsushima, Y Sakamoto, et al.
ESMO Open|August 29, 2025
A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)M Wakabayashi, H Taniguchi, A Makiyama, et al.
ESMO Open|October 24, 2025
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancersK Muro, K Chin, S B Maron, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Oncogene|November 11, 1999
Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domainsJ Yan, H Kuroyanagi, T Tomemori, et al.
Archives of Gerontology and Geriatrics|December 20, 2011
Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) studyN Kuriyama, T Mizuno, Y Ohshima, et al.
Neuron|October 18, 2001
C. elegans slit acts in midline, dorsal-ventral, and anterior-posterior guidance via the SAX-3/Robo receptorJ C Hao, T W Yu, K Fujisawa, et al.
Leukemia|January 9, 2015
High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AMLA Jo, S Mitani, N Shiba, et al.
ESMO Open|November 28, 2023
Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational studyY Narita, T Matsushima, Y Sakamoto, et al.
ESMO Open|August 29, 2025
A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)M Wakabayashi, H Taniguchi, A Makiyama, et al.
ESMO Open|October 24, 2025
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancersK Muro, K Chin, S B Maron, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Pageof 8